Citius Pharmaceuticals Inc
Citius Pharmaceuticals Inc
Your view on CTXRW
Overview
What the company does, where it operates, and who runs it.
About Citius Pharmaceuticals Inc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- NV, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Not available
- Headquarters
- NV, US
Citius Pharmaceuticals Inc. operates as an advanced-stage pharmaceutical company dedicated to the creation and commercialization of critical care therapeutics. Its strategic focus encompasses oncology, anti-infective agents for supportive cancer care, prescription drugs, and pioneering stem cell therapies. The company's pipeline features five distinct proprietary product candidates. Among these is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein currently undergoing Phase 3 clinical trials, designed to address persistent or recurrent cutaneous T-cell lymphoma. Also in Phase 3 development is Mino-Lok, an antibiotic lock solution aimed at resolving catheter-related bloodstream infections while preserving the infected catheter. Halo-Lido, a topical corticosteroid-lidocaine formulation in Phase 2b, seeks to deliver anti-inflammatory and anesthetic relief for individuals suffering from hemorrhoids. Additionally, Citius is advancing Mino-Wrap, a liquifying gel-based wrap formulated to mitigate tissue expander infections following breast reconstructive procedures, and NoveCite, a mesenchymal stem cell therapy intended for the treatment of acute respiratory distress syndrome. Cranford, New Jersey serves as the corporate headquarters for Citius Pharmaceuticals, which was established in 2007.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
FRC's fair value estimate for Citius Pharmaceuticals Inc, and the rating behind it. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Citius Pharmaceuticals Inc. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Citius Pharmaceuticals Inc. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Citius Pharmaceuticals Inc. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Citius Pharmaceuticals Inc. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Citius Pharmaceuticals Inc valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Citius Pharmaceuticals Inc, and how their positions are changing. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Citius Pharmaceuticals Inc executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Citius Pharmaceuticals Inc. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Citius Pharmaceuticals Inc. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Citius Pharmaceuticals Inc. Press releases and market coverage, newest first.